Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
Tubulin | 1 |
MMP3(Matrix metalloproteinase 3) | 1 |
Target |
Mechanism Tubulin inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MMP3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date21 Jun 2023 |
Sponsor / Collaborator |
Start Date14 Jun 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Paclitaxel-hyaluronic acid conjugate(Fidia Farmaceutici SpA) ( Tubulin ) | Carcinoma in Situ More | Phase 3 |
FID-145 ( MMP3 ) | Osteoarthritis More | Discovery |
Siagoside | Stroke More | Discontinued |
Imidazenil ( GABAA receptor ) | Epilepsy More | Discontinued |
Mipragoside | Inflammation More | Discontinued |